Evangelos Kiskinis

US Patent:

20130296183, Nov 7, 2013

Filed:

Sep 16, 2011

Appl. No.:

13/822336

Inventors:

Kevin C. Eggan - Boston MA, US
Alexander Meissner - Cambridge MA, US
Christoph Bock - Vienna, AT
Evangelos Kiskinis - Boston MA, US
Griet Annie Frans Verstappen - Moltsel, BE

Assignee:

PRESIDENT AND FELLOWS OF HARVARD COLLEGE - Cambridge MA

International Classification:

C12N 15/10

US Classification:

506 9, 506 16

Abstract:

The present invention generally relates set of reference data or “scorecard” for a pluripotent stem cell, and methods, systems and kits to generate a scorecard for predicting the functionality and suitability of a pluripotent stem cell line for a desired use. In some aspects, a method for generating a scorecard comprises using at least 2 stem cell assays selected from: epigenetic profiling, differentiation assay and gene expression assay to predict the functionality and suitability of a pluripotent stem cell line for a desired use. In some embodiments, the scorecard reference data can be compared with the pluripotent stem cells data to effectively and accurately predict the utility of the pluripotent stem cell for a given application, as well as any to identify specific characteristics of the pluripotent stem cell line to determine their suitability for downstream applications, such as for example, their suitability for therapeutic use, drug screening and toxicity assays, differentiation into a desired cell lineage, and the like.

US Patent:

20220213141, Jul 7, 2022

Filed:

Jan 24, 2020

Appl. No.:

17/425757

Inventors:

- Evanston IL, US
Kohei Sato - Yokohama, JP
Juan Alberto Ortega Cano - Chicago IL, US
Evangelos Kiskinis - Chicago IL, US
Samuel I. Stupp - Chicago IL, US

International Classification:

C07K 7/06
A61P 25/00
C12N 5/00
C12N 5/0793
A61K 35/30

Abstract:

Provided herein are peptide amphiphiles (PAs) comprising a bioactive peptide, nanofibers displaying the bioactive PAs, and methods of use thereof. The disclosed peptide amphiphiles comprise a hydrophobic tail, a structural peptide segment, a charged peptide segment, and a bioactive IKVAV peptide. The disclosed PAs may be used in cell culture methods and in methods of treating central nervous system injury.

US Patent:

20200191776, Jun 18, 2020

Filed:

Feb 24, 2020

Appl. No.:

16/798581

Inventors:

- Cambridge MA, US
Adam Cohen - Cambridge MA, US
Joel Kralj - Somerville MA, US
Evangelos Kiskinis - Cambridge MA, US

International Classification:

G01N 33/50
G01N 33/68
C12N 5/0793
G01N 33/487
G01N 21/64

Abstract:

The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but—for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease

US Patent:

20190025291, Jan 24, 2019

Filed:

Sep 13, 2018

Appl. No.:

16/130048

Inventors:

- Cambridge MA, US
Adam Cohen - Cambridge MA, US
Joel Kralj - Somerville MA, US
Evangelos Kiskinis - Cambridge MA, US

International Classification:

G01N 33/50
C12N 5/0793
G01N 21/64
G01N 33/487
G01N 33/68

Abstract:

The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease

US Patent:

20170115279, Apr 27, 2017

Filed:

Jan 4, 2017

Appl. No.:

15/398130

Inventors:

- Cambridge MA, US
Adam Cohen - Cambridge MA, US
Joel Kralj - Somerville MA, US
Evangelos Kiskinis - Cambridge MA, US

International Classification:

G01N 33/50
G01N 21/64
G01N 33/68
G01N 33/487
C12N 5/0793

Abstract:

The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease

US Patent:

20160282327, Sep 29, 2016

Filed:

May 10, 2016

Appl. No.:

15/151006

Inventors:

- Cambridge MA, US
Adam Cohen - Cambridge MA, US
Joel Kralj - Somerville MA, US
Evangelos Kiskinis - Cambridge MA, US

International Classification:

G01N 33/487
G01N 33/68
G01N 21/64
G01N 33/50

Abstract:

The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease

US Patent:

20150301028, Oct 22, 2015

Filed:

Apr 21, 2015

Appl. No.:

14/692214

Inventors:

- Cambridge MA, US
Adam Cohen - Cambridge MA, US
Joel Kralj - Somerville MA, US
Evangelos Kiskinis - Cambridge MA, US

Assignee:

Q-STATE BIOSCIENCES, INC. - Cambridge MA

International Classification:

G01N 33/50
G01N 33/68

Abstract:

The invention generally relates to optical methods for characterizing the effects of compounds on pain and other sensory phenomena. The effect of compounds on pain and other sensory phenomena may be characterized using dorsal root ganglion (DRG) neurons or sensory neurons expressing optogenetic proteins that allow neural activity to be stimulated and detected optically. The invention provides cell-based optical assays for studying the molecular and cellular bases of pain and sensory phenomena and as platforms to screen and validate drugs, e.g., for pre-clinical trials.

US Patent:

20150301029, Oct 22, 2015

Filed:

Apr 21, 2015

Appl. No.:

14/692242

Inventors:

- Cambridge MA, US
Adam Cohen - Cambridge MA, US
Joel Kralj - Somerville MA, US
Evangelos Kiskinis - Cambridge MA, US

International Classification:

G01N 33/50

Abstract:

The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease